Shares of 23andMe Holding Co. (ME) are up over 20% at $1.33 in premarket trading Friday, following FDA clearance to expand its existing BRCA1/BRCA2 Genetic Health Risk Report.
A Genetic Health Risk report indicates the presence of specific genetic variants linked to an increased likelihood of developing a disease although it does not describe a person's overall risk of developing the disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com